Dabrafenib - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Dabrafenib

Brand Name:

Tafinlar

Strength:

50 mg

HCPCS:

NA

SEER*Rx Category:

Chemotherapy

Major Drug Class:

Tyrosine Kinase Inhibitor

Minor Drug Class:

BRAF

Oral (Y/N):

Yes

FDA Approval Year:

2013

FDA Discontinuation Year:

CMS Effective Date:

Jan. 1, 2004

CMS Discontinuation Date:

Status:

In Use